Homozygous deletions within human chromosome band 9p21 in melanoma.

PubWeight™: 1.58‹?› | Rank: Top 4%

🔗 View Article (PMC 50378)

Published in Proc Natl Acad Sci U S A on November 01, 1992

Authors

J W Fountain1, M Karayiorgou, M S Ernstoff, J M Kirkwood, D R Vlock, L Titus-Ernstoff, B Bouchard, S Vijayasaradhi, A N Houghton, J Lahti

Author Affiliations

1: Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139.

Articles citing this

Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09

Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64

p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A (2012) 1.71

The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46

Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer (1997) 1.19

Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol (1996) 1.17

Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A (1996) 1.14

CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol (2001) 1.12

Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci U S A (1993) 1.09

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer (1996) 1.02

Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet (1995) 1.02

Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol (1998) 1.01

Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet (1993) 0.97

High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer (1996) 0.96

Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am J Hum Genet (1994) 0.94

Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts. Am J Hum Genet (2012) 0.93

Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn (2002) 0.92

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. Br J Cancer (2000) 0.91

Genetics of melanoma. Front Genet (2013) 0.91

MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol (1995) 0.90

Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci U S A (1994) 0.89

Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines. Mol Cell Biol (1994) 0.89

Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer (2012) 0.89

Collateral Lethality: A new therapeutic strategy in oncology. Trends Cancer (2015) 0.87

Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am J Hum Genet (1993) 0.86

Molecular clonality of in-transit melanoma metastasis. Am J Pathol (2001) 0.86

Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J Mol Diagn (2004) 0.85

Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. Proc Natl Acad Sci U S A (1994) 0.84

Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer (1999) 0.84

Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br J Cancer (1995) 0.84

Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS One (2014) 0.84

Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet (1994) 0.84

p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch (2004) 0.83

Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev (2007) 0.80

Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63. Chromosome Res (2008) 0.79

Low-frequency loss of heterozygosity in Moloney murine leukemia virus-induced tumors in BRAKF1/J mice. J Virol (1997) 0.79

Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78

Two distinct pathways of p16 gene inactivation in gallbladder cancer. World J Gastroenterol (2007) 0.77

Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization. Br J Cancer (1999) 0.77

A systems approach defining constraints of the genome architecture on lineage selection and evolvability during somatic cancer evolution. Biol Open (2012) 0.75

Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death. Oncoimmunology (2017) 0.75

Articles cited by this

A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96

Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell (1990) 8.30

The synthesis of complex carbohydrates by multiglycosyltransferase systems and their potential function in intercellular adhesion. Chem Phys Lipids (1970) 4.64

Report of the committee on the genetic constitution of chromosomes 9 and 10. Cytogenet Cell Genet (1989) 3.79

Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A (1988) 3.67

A cDNA encoding tyrosinase-related protein maps to the brown locus in mouse. Proc Natl Acad Sci U S A (1988) 2.72

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44

A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer (1983) 1.87

Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med (1990) 1.82

Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65

Nucleotide sequence of the cDNA encoding human tyrosinase-related protein. Nucleic Acids Res (1990) 1.60

Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17. Am J Hum Genet (1989) 1.54

Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A (1985) 1.39

Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res (1991) 1.38

Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations. Cancer Genet Cytogenet (1986) 1.38

The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant and diploid cells and of tumours derived from them. J Cell Sci (1977) 1.35

Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34

Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res (1991) 1.25

Glycoproteins as differentiation markers in human malignant melanoma and melanocytes. Cancer Res (1983) 1.23

Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res (1992) 1.22

Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci U S A (1989) 1.21

Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons. Cancer Res (1990) 1.11

Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer (1990) 1.10

Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res (1987) 1.09

Genetic and physical map of the interferon region on chromosome 9p. Genomics (1992) 1.07

Monochromosomal rodent-human hybrids from microcell fusion of human lymphoblastoid cells containing an inserted dominant selectable marker. Genomics (1990) 1.05

Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization. Genomics (1992) 1.03

Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst (1988) 1.02

Genetics of melanoma. Cancer Surv (1990) 1.00

Cell-surface glycosyltransferases in cultured fibroblasts: increased activity and release during serum stimulation of growth. Proc Natl Acad Sci U S A (1977) 0.98

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med (1985) 0.98

Normal human epidermis contains an interferon-like protein. J Cell Biol (1986) 0.92

Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer (1986) 0.86

Consistent karyotypic abnormalities in human malignant melanomas. Anticancer Res (1990) 0.83

Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemia. Leukemia (1991) 0.83

The human homolog of the mouse brown gene maps to the short arm of chromosome 9 and extends the known region of homology with mouse chromosome 4. Genomics (1991) 0.82

Construction and characterization of radiation hybrids for chromosome 9, and their use in mapping cosmid probes on the chromosome. Somat Cell Mol Genet (1992) 0.82

Beta 1-4-galactosyltransferase gene expression is regulated during entry into the cell cycle and during the cell cycle. Somat Cell Mol Genet (1991) 0.80

Chromosomal evolution in the progression and metastasis of human malignant melanoma. A multiple lesion study. Cancer Genet Cytogenet (1989) 0.79

Deletion of alpha-, beta-, and omega-interferon genes in malignant cells from children with acute lymphocytic leukemia. Cancer Res (1990) 0.79

Loss of heterozygosity at polymorphic chromosomal loci in patients with malignant melanoma. J Invest Dermatol (1989) 0.78

Articles by these authors

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A (1998) 3.99

LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia. Mol Psychiatry (2007) 3.49

Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev (2001) 3.40

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27

Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis (1994) 3.12

Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65

Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37

Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20

Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19

Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med (1992) 2.09

Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry (2008) 2.07

Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06

Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02

Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98

Electric blanket or mattress cover use and breast cancer incidence in women 50-79 years of age. Epidemiology (2001) 1.96

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92

Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86

Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. Am J Med Genet (1994) 1.86

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85

Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81

Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76

Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73

Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71

The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet (1999) 1.67

Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59

Over-the-counter analgesics and risk of ovarian cancer. Lancet (1998) 1.59

Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59

Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control (2000) 1.56

Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54

Music and emotion: perceptual determinants, immediacy, and isolation after brain damage. Cognition (1998) 1.54

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (1993) 1.52

A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51

Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48

Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

Reproductive factors and histologic subtype in relation to mortality after a breast cancer diagnosis. Breast Cancer Res Treat (2011) 1.45

Age at any full-term pregnancy and breast cancer risk. Am J Epidemiol (2000) 1.44

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43

Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proc Natl Acad Sci U S A (1985) 1.39

Follow-up of a report of a potential linkage for schizophrenia on chromosome 22q12-q13.1: Part 2. Am J Med Genet (1994) 1.39

Human melanocytes cultured from nevi and melanomas. J Invest Dermatol (1986) 1.36

Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods (2004) 1.36

Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Crit Rev Toxicol (1995) 1.35

Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34

A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med (1999) 1.33

Cancer risk in women exposed to diethylstilbestrol in utero. JAMA (1998) 1.32

Genital talc exposure and risk of ovarian cancer. Int J Cancer (1999) 1.31

Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst (2001) 1.30

Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am (1984) 1.30

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29

Organochlorine compounds and estrogen-related cancers in women. Cancer Causes Control (1995) 1.27

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res (2000) 1.26

Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A (2000) 1.26

Environmental endocrine modulators and human health: an assessment of the biological evidence. Crit Rev Toxicol (1998) 1.25

Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24

In vivo description of dendritic cells in human renal cell carcinoma. J Urol (1999) 1.23

Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22

Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22

Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22

Fracture history and risk of breast and endometrial cancer. Am J Epidemiol (2001) 1.22

Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature (1987) 1.21

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19

Evolutionary conservation of antigen recognition: the chicken T-cell receptor beta chain. Proc Natl Acad Sci U S A (1990) 1.18

Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry (2007) 1.18

Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States). Cancer Causes Control (2001) 1.17

A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15

Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery (2000) 1.15

Metabolic disorders and breast cancer risk (United States). Cancer Causes Control (2001) 1.14

Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission. Nature (2014) 1.14

The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav (2004) 1.14

Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14

A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med (1993) 1.13

A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12